Amarin Shareholders Reject Dilution, Governance Proposals at AGM

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Amarin ( (AMRN) ) just unveiled an update. At its May 13, 2026 annual general meeting, Amarin shareholders rejected proposals to expand the board’s authority to issue new shares, increase the 2020 Stock Incentive Plan, disapply U.K. pre‑emption rights, and shift to electronic delivery of AGM materials, while still re‑electing key directors and narrowly backing executive pay. The votes significantly constrain the board’s ability to grant equity‑based incentives, forcing a greater reliance on cash compensation that will weigh on the company’s cash position, and will also keep Amarin incurring ongoing printing and mailing costs, signaling clear shareholder resistance to further dilution and governance changes. The most recent analyst rating on (AMRN) stock is a Sell with a $12.00 price target. To see the full list of analyst forecasts on Amarin stock, see the AMRN Stock Forecast page. Spark’s Take on AMRN Stock According to Spark, TipRanks’ AI Analyst, AMRN is a Neutral. The score is held back primarily by persistent unprofitability and weak technical trend signals (below key moving averages with negative MACD). Offsetting these, the balance sheet is strong with very low debt and cash-flow trends improved, and the latest earnings call added confidence via cost-savings progress, continued positive operating cash flow, and positive full-year 2026 cash-flow guidance. To see Spark’s full report on AMRN stock, click here. More about Amarin Amarin Corporation plc is a biopharmaceutical company focused on cardiovascular health, best known for developing and commercializing therapies derived from omega‑3 fatty acids. The company’s primary product targets patients at elevated cardiovascular risk, with a commercial footprint centered on the U.S. and key international markets through prescription‑based therapies. Average Trading Volume: 74,413 Technical Sentiment Signal: Sell Current Market Cap: $310.1M For a thorough assessment of AMRN stock, go to TipRanks’ Stock Analysis page.